APP and Alzheimer disease: In addition, one preclinical study showed that peripheral administration of antisense oligonucleotides (ASO) targeting AβPP reversed AβPP and low-density lipoprotein-related protein-1 (LRP-1) overexpression in the aged SAMP8 mouse of AD (Erickson et al. 2012).